Skip to main content

Table 2 Summary of ceftolozane and tazobactam steady-state pulmonary ELF exposures in patients with HABP/VABP

From: Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Exposure measure

Statistic

Ceftolozane

Tazobactam

CrCl ≥ 80 to < 150 mL/min

CrCL ≥ 150 to < 180 mL/min

CrCL ≥ 180 to < 210 mL/min

CrCL ≥ 210 mL/min

CrCl ≥ 80 to < 150 mL/min

CrCL ≥ 150 to < 180 mL/min

CrCL ≥ 180 to < 210 mL/min

CrCL ≥ 210 mL/min

AUC0–8 (μg × h/mL)

n

138

24

16

20

138

24

16

20

Geometric mean (geometric %CV)

199 (78.9)

149 (64.0)

127 (86.6)

118 (69.6)

24.7 (108)

14.4 (72.1)

16.0 (85.9)

13.6 (77.5)

Cmax (μg/mL)

n

138

24

16

20

138

24

16

20

Geometric mean (geometric %CV)

28.3 (78.8)

21.0 (69.8)

17.4 (87.8)

15.9 (71.7)

4.68 (107)

2.78 (65.7)

3.31 (92.9)

2.81 (85.6)

  1. Among all participants from the intention-to-treat population who had pharmacokinetic data collected
  2. AUC0–8, area under the concentration–time curve from time 0 to 8 h after start of infusion; Cmax, maximum drug concentration; CrCl, creatinine clearance; CV, coefficient of variation; ELF, epithelial lining fluid; HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia